IMC Titanium Stent long life reasonable cost IMC International - PowerPoint PPT Presentation

IMC Titanium Stent long life reasonable cost IMC – International Medical Contrivances 1

IMC Cardiovascular Stent Type : Titanium Oxynitride Coating Stent Platform : 316 L Stainless steel alloy or L605 Cobalt Chromium Alloy Technology : Single Layer Physical Vapor Deposition PVD coating, patented by IMC.  Product could be based either on : • a OEM Stent design, already tested and approved, • Or a new stent design to finalize the development and approval. The new developed type of Titaniumoxinitrid is not consumed, it creates a biocompatible permanent coating IMC – International Medical Contrivances 2

 Product could be based either on : • an OEM classic Stent, already tested and approved, • or based on a new stent design subject to development and approval. IMC – International Medical Contrivances 3

Types of Stents Bare Metal Stents BMS  Drug Eluting Stents DES  Other Titanium Oxide nitride coated stents with multiple  layer coating Bare Metal Stents BMS induce a metallic foreign body reaction, which can be avoided by the use of titanium nitride oxide coating and decrease the Restenosis & thrombosis rates  main drawbacks of BMS  High late loss  high rate of thrombosis  adverse reactions IMC 4

Any DES Stent becomes after eluting the drug components a BMS Stent , approximately 9 months Main drawbacks, worst to BMS :  unexplained late thrombosis  Negative Late loss  Patient under life time medication ( cost and side effects) High cost for the patient & the insurance for Abbot Stent p.e. cost of medication is about 2200 USD per year  Ineffective drug elution and no possible process of stent endothelization 5

 Hexacath  IMC Titanium Stent Multilayer with constant Single layer with varying   stoichometry stoichometry Total thickness 250nm Total thickness max 50nm   RF- Magnetron Sputtering Filtered Arc Deposition RF   Magnetron 180 -200eV Energy of particles 2-12eV   1-2nm Substrate penetration 0,05nm   One interface Nine coating interfaces   Less than 2% Desctructive quality control 10%   +/- 5% Coating uniformity +/-20%   45 min Time per coating run 90min   6

 Enhanced Stent Bioactivity and Biocompatibility in synergy with an improved stent coating Biomechanics 7

The new technology is patented through  EP 249 1161 &  Eurasia patent 201200502  other countries pending  IMC International Medical Contrivances SA, is owning the IP- rights, and supporting the development of this new technology 8

9

10

11

Exemple : coupe à travers une artère après l’implantation d’un stent (points noirs). Une couche protectrice de cellules s’est déjà formée au -dessus du stent. 12

Source : « Stents coronariens biorésorbables : une révolution ? », F. Koegler, E. De Benedett, Rev Med Suisse 2013 ; 9 : 775-8 13

IMC C has develo veloped ped th the e new ew sten tent t coat oatin ing g te tech chnolo logy gy to toget gether her with th leadin ading g specialis ecialists s in the indu dustry try CON ONCEPT EPT: Locally produce the Stent in key markets under a license for the use of the Patent and to transfer the know how to the Licensee ´ s personnel. IMC will build for the client a modular Production Line; that can after the completion of training and start up, be simply relocated . To ac To achieve ieve this: s: IMC offers to set up the production line in Switzerland in a modular system, tailor made to client ´ s needs and a 6 Months to one year training and know how transfer to the personnel selected by the client. Thereafter the modular production line can be transferred to the country of destination Stent production will be accompanied by the specialists under the License Agreement 14

HARDWARE; PATENT – LICENSE SE; KNOW-HOW  Turn key modular coating facility for the new generation IMC Titanium Stent  Training and know how transfer for your personnel  Patent- License for your target market  Ongoing technical and production support  Scientific data and regulatory support for the local approvals of the stents The training is offered by a team of professionals working with IMC, well acquainted with the patent and with many years experience in the industry 15

Dr. . Joha hann nn La Lamm mmer er  1972 Dr. phil. . In Physi ysics cs at the Univer iversity sity Graz z Austria ria  Since ce 1973 speci cialize alized d in surfa face ce treatment tment and d co coat ating ng tec echnology nology  Univer iversity sity of Lausan sanne ne  LSHR HR ( L Labora oratoir toire Suisse se de rech charge arge horloger ogere)  Inventor nventor of the e co coat atings ngs for the e Hex exacath acath Stents ents  Inve nventor ntor and superv ervisor sor of the technol chnological ogical applicat ication ion for the new IMC C Stent 16

Dr. . M Mustapha tapha Mekki  PhD in Chemistry , University of Geneva  R&D Project Management in leading stent developments  Project Leader and Production Manager of one of the main European stent producers  Biomaterials Lab Researcher University of Geneva 17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

Share e sales agreem ement ent with option on for asset deal upon pon completio tion of of IMC IMC training TRUSTEE STEE Buyer License se Guarantee ee wi with shares es agreem emen ent SPV

IMC IMC Credit line for equipment ent & & training cost License se agreem ement ent for patent t & know know TRUSTEE STEE Buyer how how Selec ect t and send d person sonnel nel for Instruc ructo tors rs & & SPV training Specialist sts Supplies es OEM producer cer Producti ction on line

License nse IMC IMC Buyer Opera rati ting ng company ny SPV Producti ction on line

Share e purchase se agreem emen ent IMC IMC License se agreem emen ent for Buyer patent Instruc ructo tors rs & & SPV Specialists sts Supplies es OEM producer cer

 IMC sets up up the SPV V in Geneva eva Switzer tzerland land  You enter into a a sales purchase chase agreemen ement, , gran anting ting yo you the irrev evocable cable option ion for a a shar are or or an asset deal after r the comp mpleti etion on of of the traini ning ng  SPV obta taine ines Patent nt and Know ow How lice cense nse for your tar yo arget et mar arket ket  SPV acq cquir uires es the steril il room om faci ciliti lities es and the equipm pment nt requir ired ed, , financ nced ed by by yo you.  You ar are sec ecured red through ough a a trustee stee arrangement gement with a a swiss trustee tee jointly tly selected cted 37

 IMC coordinates for SPV all arrangements with all relevant suppliers  After successful basis-training – >production starts  When standards are achieved -> SPV may starts selling the stents  Training is continued until your crew is able to produce the product without supervision  Finally you decide Asset Deal <-> Share Deal 38

 SPV sells equipment at acquisition cost to you  SPV assigns license for target market to you  SPV assigns existing loan agreements to you 39

 You buy the shares in the fully licensed SPV  IMC grants you the right to assign the rights pertaining to the SPV.  Then you can decide how you transfer the modular production line best  or f.e. keep the SPV for acquisition and trading purposes 40

People Function 1 Quality control reception 2 Operator Coating Machines 2 Assembly 1 Packaging 1 Quality Control 1 Supervisor- Production Coordinator 1 Logistic – supply chain 41

IMC International Medical Contrivances S.A. 25 Montée de Clausen L – 1343 Luxembourg Contact: Gerd Schneider Director +352 661 65 11 17 Mail :g.schneider@azurfive.com 42